Key Highlights

  • Total revenues were USD 127,655 thousand versus 110,329 thousand, and product sales, net, were USD 125,455 thousand versus 105,515 thousand.
  • Income from operations was USD 4,023 thousand versus USD 4,668 thousand, with Research and Development expense of USD 25,199 thousand.
  • Net loss was USD 737 thousand versus 969 thousand, and net loss per share was USD 0.00 in both quarters.
  • Cash, cash equivalents and short-term investments totaled USD 285,338 thousand at September 30, 2026, compared with 264,689 thousand at year-end.

Revenues

Ardelyx, Inc. (NASDAQ:ARDX), a commercial-stage biopharmaceutical company Marketing two therapies from the active ingredient tenapanor, IBSRELA and XPHOZAH, filed its Quarterly Report for the period ended September 30, 2026. Total revenues for the third quarter were USD 127,655 thousand, compared with USD 110,329 thousand in the third quarter of 2025.

Product sales, net, were USD 125,455 thousand versus USD 105,515 thousand. Product Supply Revenue was USD 1,380 thousand, with none in the prior-year quarter. Licensing revenue was USD 216 thousand versus USD 25 thousand, and non-cash Royalty revenue related to the sale of future royalties was USD 604 thousand versus USD 4,789 thousand.

For the nine months, total revenues were USD 343,005 thousand versus USD 282,105 thousand, and product sales, net, were USD 336,957 thousand versus USD 263,406 thousand.

Analyst estimates were EPS of negative USD 0.02 against reported EPS of USD 0.00, and revenue of USD 128.0 million against reported revenue of USD 127.7 million.

Costs, Operating Income and Net Loss

Cost of sales was USD 4,539 thousand versus USD 3,982 thousand. Research and development expense was USD 25,199 thousand versus USD 18,067 thousand, and selling, general and administrative expense was USD 93,894 thousand versus USD 83,612 thousand. Total costs and operating expenses were USD 123,632 thousand versus USD 105,661 thousand.

Income from operations was USD 4,023 thousand versus USD 4,668 thousand. Interest expense was USD 5,880 thousand versus USD 5,796 thousand, and non-cash interest expense related to the sale of future royalties was USD 1,502 thousand versus USD 2,188 thousand. Other income, net, was USD 2,712 thousand versus USD 2,449 thousand.

The loss before provision for income taxes was USD 647 thousand versus USD 867 thousand, and the net loss was USD 737 thousand versus USD 969 thousand. Basic and diluted net loss per share was USD 0.00 in both periods, on 250,007,187 shares versus 241,908,407.

For the nine months, the loss from operations was USD 41,195 thousand versus USD 46,076 thousand, and the net loss was USD 55,063 thousand versus USD 61,192 thousand, or USD 0.22 per share versus USD 0.25.

Cash, Liquidity and Debt

Cash and cash equivalents were USD 46,317 thousand at September 30, 2026, compared with USD 67,999 thousand at December 31, 2025, and short-term investments were USD 239,021 thousand versus USD 196,690 thousand. Total liquid funds were USD 285,338 thousand versus USD 264,689 thousand.

Net cash used in Operating Activities for the nine months was USD 36,465 thousand versus USD 63,434 thousand. Net cash used in investing activities was USD 41,338 thousand versus USD 12,735 thousand, and net cash provided by financing activities was USD 56,121 thousand versus USD 53,952 thousand.

The Loan and security agreement with SLR provides for total borrowings of up to USD 300.0 million, of which USD 250.0 million was drawn and outstanding as of September 30, 2026, including USD 50.0 million of the Term F Loan drawn in the second quarter. An additional USD 50.0 million Term G Loan is available at the company's election through December 20, 2026. No shares were sold under the at-the-market Sales Agreement of up to USD 100.0 million.

Items to Follow

The company listed its priorities as driving IBSRELA growth, maintaining XPHOZAH commercial momentum, advancing its pipeline and maintaining its financial foundation. Investors can follow product sales, net, which were USD 125,455 thousand in the quarter, and research and development expense.

Other items include the availability of the USD 50.0 million Term G Loan through December 20, 2026, and the company's statement that it expects to rely increasingly on cash generated from commercial operations to fund its operating plan.